NPR1.F - INSYS Therapeutics, Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.0600
-0.0040 (-6.25%)
As of 8:18AM CET. Market open.
Stock chart is not supported by your current browser
Previous Close0.0640
Open0.0600
Bid0.0600 x 30000
Ask0.0760 x 30000
Day's Range0.0600 - 0.0600
52 Week Range0.0304 - 6.0100
Volume8,200
Avg. Volume7,146
Market Cap3.978M
Beta (3Y Monthly)2.44
PE Ratio (TTM)N/A
EPS (TTM)-3.0710
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Drugmaker Insys wins bankruptcy court approval to sell off opioid
    Reuters

    Drugmaker Insys wins bankruptcy court approval to sell off opioid

    The decision by U.S. Bankruptcy Judge Kevin Gross in Wilmington, Delaware, marked the first time a bankruptcy court approved the sale of an opioid amid an epidemic that has been blamed for nearly 400,000 overdose deaths between 1999 and 2017. The ruling cleared the way for the drug, Subsys, to be sold to Wyoming-based BTcP Pharma LLC, which belongs to the MMB Healthcare network of pharmaceutical companies. In exchange, Insys will receive royalties it estimated could reach $20 million.

  • Opinion: Medical Marijuana Is a Terrible Investment
    Motley Fool

    Opinion: Medical Marijuana Is a Terrible Investment

    Medical marijuana drug developers are often smothered in hype and rarely deliver any reward.

  • TheStreet.com

    Insys Therapeutics Sinks After Filing for Bankruptcy

    was down 36% in trading Monday after the company announced it will be filing for Chapter 11 bankruptcy protection due to the financial burden from litigation tied to its role in the opioid crisis in the United States. It said it would continue to operate its business "in the ordinary course" while it sells off its assets through bankruptcy court. Just last week, Insys agreed to pay $225 million to settle federal charges over its opioid sales.

  • Opioid manufacturer Insys files for bankruptcy after kickback probe
    Reuters

    Opioid manufacturer Insys files for bankruptcy after kickback probe

    The Chapter 11 bankruptcy filing marked a first for a drugmaker accused in lawsuits of helping fuel the deadly U.S. opioid endemic and came just days after Insys struck a $225 million settlement with the Justice Department. The department is now Insys' largest unsecured creditor due to Wednesday's accord, which resulted in a subsidiary pleading guilty to fraud charges and the company entering into a deferred prosecution agreement. The bankruptcy filing came after a federal jury in Boston in May found Insys founder John Kapoor and four other former executives guilty of engaging in a racketeering conspiracy centered on its fentanyl spray, Subsys.

  • Reuters

    UPDATE 4-Opioid manufacturer Insys files for bankruptcy after kickback probe

    Drugmaker Insys Therapeutics Inc filed for bankruptcy protection on Monday amid mounting expenses driven by a U.S. Justice Department probe into claims it paid doctors bribes to prescribe a powerful opioid medication. The Chapter 11 bankruptcy filing marked a first for a drugmaker accused in lawsuits of helping fuel the deadly U.S. opioid endemic and came just days after Insys struck a $225 million settlement with the Justice Department. The department is now Insys' largest unsecured creditor due to Wednesday's accord, which resulted in a subsidiary pleading guilty to fraud charges and the company entering into a deferred prosecution agreement.

  • 3 Marijuana Stocks I Wouldn't Touch With a 10-Foot Pole Right Now
    Motley Fool

    3 Marijuana Stocks I Wouldn't Touch With a 10-Foot Pole Right Now

    Some marijuana stocks are worth a serious look. These aren't.

  • 3 Marijuana Stocks Hitting All-Time Lows
    Motley Fool

    3 Marijuana Stocks Hitting All-Time Lows

    Though many cannabis investors are seeing green, these pot stocks have gone up in smoke.

  • Why Insys Therapeutics Fell More than 70% Yesterday
    Market Realist

    Why Insys Therapeutics Fell More than 70% Yesterday

    Why Insys Therapeutics Fell More than 70% YesterdayLiquidity positionIn its first-quarter earnings press release, which it published on May 10, Insys Therapeutics (INSY) highlighted the possibility of its being unable to continue as a going concern.

  • Why Insys Therapeutics Stock Is Crashing Today
    Motley Fool

    Why Insys Therapeutics Stock Is Crashing Today

    The biotech raised the possibility of filing for bankruptcy in its latest earnings report.

  • CNBC

    Drugmaker Insys shares tank after saying opioid lawsuits may force it into bankruptcy

    A Boston jury convicted Insys founder John Kapoor and four former executives of racketeering and other crimes in a fentanyl bribery case that federal prosecutors say helped fuel the U.S. opioid epidemic. Insys Therapeutics INSY shares tanked Monday morning after the company said it may have to file for bankruptcy because it can't afford legal costs related to a Department of Justice investigation into the company's sales tactics of one of its popular opioids. Insys said it had $87.6 million in cash and cash equivalents at the end of March, which falls short of the $150 million tentative settlement the company made with the Department of Justice to settle claims that the company bribed doctors to unnecessarily prescribe its fentanyl-based drug Subsys, which is meant to treat cancer patients.

  • TheStreet.com

    Opioid Maker Insys Sinks After Saying It May Be Forced to File Bankruptcy

    The company also said it was uncertain that it will be able to complete a final settlement with the Department of Justice, including the execution of a security agreement related to the company's assets to collateralize payments under the settlement. "If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our audited consolidated financial statements, and it is likely that investors will lose all or a part of their investment," the company said in its first-quarter earnings release. Insys added: "It may be necessary for the company to file a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in order to implement a restructuring.

  • Investing $1,000 Into This Marijuana Stock in 2016 Would Leave You With Pennies on the Dollar Today
    Motley Fool

    Investing $1,000 Into This Marijuana Stock in 2016 Would Leave You With Pennies on the Dollar Today

    This once-promising pot stock may not survive the year.

  • Insys says it may be forced to file for bankruptcy due to litigation cash crunch
    Reuters

    Insys says it may be forced to file for bankruptcy due to litigation cash crunch

    Insys, which has been exploring strategic options and is in talks to divest its opioid product Subsys, said it was likely that investors will lose all or a part of their investments if the company is not able to sell its assets at the value they are booked in its audited financial statements. Last August, Insys reached a tentative deal to pay at least $150 million to resolve a Department of Justice investigation into claims that the drugmaker paid doctors kickbacks to prescribe Subsys, an under-the-tongue spray that contains fentanyl, an opioid 100 times stronger than morphine.

  • Associated Press

    Insys Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the Chandler, Arizona-based company said it had a loss of $1.66. Losses, adjusted for one-time gains and costs, were 55 cents per share. The specialty pharmaceutical company posted ...

  • Founder, execs of drug company guilty in conspiracy that fed opioid crisis
    Reuters

    Founder, execs of drug company guilty in conspiracy that fed opioid crisis

    The founder of Insys Therapeutics Inc on Thursday became the highest-ranking pharmaceutical executive to be convicted in a case tied to the U.S. opioid crisis, when he and four colleagues were found guilty of participating in a scheme to bribe doctors to prescribe an addictive painkiller. A federal jury in Boston found John Kapoor, the drugmaker's former chairman, and his co-defendants guilty of racketeering conspiracy for engaging in a scheme that also misled insurers into paying for the drug. Kapoor's 2017 arrest came on the same day U.S. President Donald Trump declared the epidemic that has caused tens of thousands of overdose deaths annually a public health emergency.

  • Top Trending: Insys files for bankruptcy, Hudson's Bay offers to go private and more
    Yahoo Finance Video

    Top Trending: Insys files for bankruptcy, Hudson's Bay offers to go private and more

    Yahoo Finance's Adam Shapiro fills you in on the top trending news stories that you need to know.